Tandem Diabetes Care Stock News

Tandem Diabetes Care Inc (NASDAQ: TNDM ) reported Q4 sales reached $209.9 million , +25% Y/Y, beating the consensus of $199.12 million. The Company posted EPS of $0.16, down from $0.22 a year ago, and missed the Wall Street estimate of $0.21. Worldwide pump shipments … Full story available on Benzinga.com

Over the past 3 months, 4 analysts have published their opinion on Tandem Diabetes Care (NASDAQ:TNDM) stock. These analysts are typically employed by large Wall Street banks and tasked with understand

Over the past 3 months, 4 analysts have published their opinion on Tandem Diabetes Care (NASDAQ: TNDM ) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company''s business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 2 1 0 0 Last 30D 1 1 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 1 0 0 0 3M Ago 0 0 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, Tandem Diabetes Care has an average price target of $150.25 with a high of $166.00 and a low of $120.00. Below is … Full story available on Benzinga.com

Robust domestic and international pump shipments are driving Tandem Diabetes' (TNDM) fourth-quarter top line.

Robust domestic and international pump shipments are driving Tandem Diabetes' (TNDM) fourth-quarter top line.

Tandem Diabetes Care, Inc. (TNDM) CEO John Sheridan on Q4 2021 Results - Earnings Call Transcript

Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of -20% and 6.08%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the st

Shares of Tandem Diabetes Care (TNDM) are up in after-hours trading even though the company missed on the bottom line in its Q4 2021 earnings.

You should read the following discussion and analysis together with "Selected Financial Data" in Part II, Item 6 and our consolidated financial statements and related notes in Part II, Item 8. The following discussion contains forward-looking statements, which statements are subject to considerable risks and uncertainties. Future filings with the SEC, The post TANDEM DIABETES CARE INC 10-K Management''s Discussion and Analysis of Financial Condition and Results of Operations. appeared first on InsuranceNewsNet .

Tandem Diabetes Care press release (TNDM): Q4 GAAP EPS of $0.16 misses by $0.06.Revenue of $210M (+24.9% Y/Y) beats by $11.17M.

Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of -20% and 6.08%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the st

Tandem Diabetes Care (NASDAQ:TNDM) is scheduled to announce Q4 earnings results on Tuesday, February 22nd, after market close.The consensus EPS Estimate is $0.21 and the consensus

Riding The Stock Waves: Update On The Medical Devices Sector

WASHINGTON, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Vantage Market Research''s recent analysis of the global Artificial Pancreas Device System Market finds that, increasing prevalence of diabetes is expediting market growth. The market growth is attributed to increasing population across the globe as well as lack of precise effective substitute. Total global Artificial Pancreas Device System Market is estimated to reach USD 415.8 Million by 2028. The Market stood at a revenue of USD 95.6 Million in 2021, and is expected to grow at a Compound Annual Growth Rate (CAGR) of 13.1%. Furthermore, rising demand for automated systems for glycemic control, as well as increasing funding in Research and Development (R&D) is projected to augment growth of the global Artificial Pancreas Device System Market, states Vantage Market Research, in a report, titled " Artificial Pancreas Device System Market by Device (Threshold Suspended Device System, CTR System, CTT System), by Region (North America, Europe, Asia Pacific, Latin America) - Global Industry Assessment (2016 - 2021) & Forecast (2022 - 2028)".